Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 8/20 | 0.64 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KDM5A | P29375 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13242298 | 0.87 | DRD4 (0.66) | NAMPTEPHX1DRD4HPGDRAB9A | |
| SCHEMBL359497 | 0.85 | ALDH1A1 (0.51) | NAMPTDRD4P2RX7ALDH1A1 | |
| SCHEMBL1908695 | 0.84 | DRD4 (0.52) | NAMPTEPHX1MAPTDRD4HPGD | |
| SCHEMBL1908664 | 0.83 | NAMPT (0.47) | NAMPTEPHX1MAPT | |
| SCHEMBL1908724 | 0.81 | SMN1; SMN2 (0.50) | NAMPTEPHX1DRD4HPGDRAB9A | |
| SCHEMBL1908665 | 0.81 | F2 (0.49) | NAMPTEPHX1DRD4HPGDRAB9A | |
| SCHEMBL20388982 | 0.80 | NAMPT (0.69) | NAMPT | |
| SCHEMBL1908655 | 0.80 | EPHX1 (0.61) | NAMPTEPHX1ALDH1A1 | |
| SCHEMBL4975754 | 0.80 | EPHX1 (0.53) | NAMPTEPHX1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL360442 | 0.79 | SSTR1 (0.53) | NAMPTEPHX1DRD4HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-8114877-B2 | Antiinflammatory agnets; chronic obstructive pulmonary diseases | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-8114877-B2 | Antiinflammatory agnets; chronic obstructive pulmonary diseases | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| US-20090240045-A1 | Organic Compounds | NOVARTIS AG | 2009-09-24 | — | — | US | disclosed |
| US-20090240045-A1 | Organic Compounds | NOVARTIS AG | 2009-09-24 | — | — | US | disclosed |
| US-20090093633-A1 | Organic Compounds | NOVARTIS AG | 2009-04-09 | — | — | US | disclosed |
| US-20090093633-A1 | Organic Compounds | NOVARTIS AG | 2009-04-09 | — | — | US | disclosed |
| US-20080242683-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-20080242683-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-20080207648-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
| US-20080207648-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
| WO-2007121918-A2 | USE OF 2-(PURIN-9-YL)-TETRAHYDOFURAN-3,4-DIOL DERIVATIVES AS ADENOSINE A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007121920-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242683-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | NAMPT 2823/4885EPHX1 1079/4885MAPT 4355/4885 |
| US-20090093633-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | NAMPT 1763/4885EPHX1 1339/4885MAPT 3049/4885 |
| US-20100286126-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | NAMPT 2588/4885EPHX1 2576/4885MAPT 1870/4885 |
| US-20090240045-A1 | Organic Compounds | CYP3A43, CYP3A4, SLCO1B3 | NAMPT 2840/4885EPHX1 2693/4885MAPT 1867/4885 |
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | NAMPT 2588/4885EPHX1 2576/4885MAPT 1870/4885 |
| US-20080207648-A1 | Organic Compounds | ADORA2A, ADORA1, ADORA3 | NAMPT 2644/4885EPHX1 1066/4885MAPT 4032/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | NAMPT 2588/4885EPHX1 2576/4885MAPT 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.